Scholarlink

<p>This study examined biomarker alteration prevalence, treatment patterns, and clinical outcomes among patients with hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2−) metastatic breast cancer to investigate racial differences. Analysis of 2,384 patients from the Flatiron Health-Foundation Medicine clinico-genomic database (FH-FMI CGDB) (2017-2022) assessed <i>PIK3CA</i>, <i>AKT1</i>, <i>PTEN</i>, <i>ESR1</i>, and <i>BRCA1/2</i> alterations via NGS testing. Treatment patterns and overall survival were evaluated. In the study population (13% Black, 87% White), Black patients had lower <i>PIK3CA</i> mutation rates (34% vs. 42%, <i>p</i> = 0.03). In first-line treatment, Black patients were less likely to receive CDK4/6 inhibitors (53% vs. 66%, <i>p</i> &lt; 0.01) and more likely to receive chemotherapy (27% vs. 17%, <i>p</i> &lt; 0.01). After adjustment, Black patients had 38% lower odds of receiving first-line CDK4/6 inhibitors and experienced significantly shorter median overall survival (34.1 vs. 42.1 months, <i>p</i> &lt; 0.01). Significant differences exist in biomarker prevalence, treatment access, and survival outcomes in HR+/HER2− metastatic breast cancer by race, highlighting unmet medical needs.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Racial differences in biomarkers, treatment, and outcomes in HR+/HER2- metastatic breast cancer in the United States

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月23日

查看全文
  • Pegah Farrokhi,
  • Leah Park,
  • Weston Schmutz,
  • Samantha L. Thompson,
  • Clara Lam,
  • Julian Bryan,
  • David D. Stenehjem

摘要

This study examined biomarker alteration prevalence, treatment patterns, and clinical outcomes among patients with hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2−) metastatic breast cancer to investigate racial differences. Analysis of 2,384 patients from the Flatiron Health-Foundation Medicine clinico-genomic database (FH-FMI CGDB) (2017-2022) assessed PIK3CA, AKT1, PTEN, ESR1, and BRCA1/2 alterations via NGS testing. Treatment patterns and overall survival were evaluated. In the study population (13% Black, 87% White), Black patients had lower PIK3CA mutation rates (34% vs. 42%, p = 0.03). In first-line treatment, Black patients were less likely to receive CDK4/6 inhibitors (53% vs. 66%, p < 0.01) and more likely to receive chemotherapy (27% vs. 17%, p < 0.01). After adjustment, Black patients had 38% lower odds of receiving first-line CDK4/6 inhibitors and experienced significantly shorter median overall survival (34.1 vs. 42.1 months, p < 0.01). Significant differences exist in biomarker prevalence, treatment access, and survival outcomes in HR+/HER2− metastatic breast cancer by race, highlighting unmet medical needs.